TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34498946

Group type: EXPERIMENTAL
Intervention: rHuEPO (400 IU/kg body wt) injection
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: In vitro incubation with rHuEPO
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acute rHuEPO injection
Number of subjects: 8
Study: 35281985

Group type: EXPERIMENTAL
Intervention: Intraparenchymal injection of placenta MSC-derived Exosome
Number of subjects: 5
Study: 33165006

Group type: EXPERIMENTAL
Intervention: Oral sulfate tablets (OST) - 24 tablets total, 12 tablets in the evening and 12 tablets the following morning, with 16 oz. of water with each dose and an additional 32 oz. of water with each dose.
Number of subjects: 515

Group type: COMPARATOR
Intervention: PEG3350, electrolytes, and ascorbate (PEG‐EA) - 1 L of prep solution with 16 oz. of additional water in the evening and again in the morning.
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Oral sulfate tablets (OST)
Number of subjects: 515

Group type: COMPARATOR
Intervention: PEG3350, electrolytes, and ascorbate (PEG‐EA)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Oral sulfate tablets (OST) and PEG3350, electrolytes, and ascorbate (PEG‐EA)
Number of subjects: 515
Study: 34894771

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (oral diazepam 5 mg and i.m. injection of pethidine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined (acupuncture + control drugs)
Number of subjects: 60
Study: 34595526

Group type: EXPERIMENTAL
Intervention: Intubation SURfactant Extubation (InSurE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Less Invasive Surfactant Administration (LISA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (InSurE and LISA)
Number of subjects: 40
Study: 33609115

Group type: EXPERIMENTAL
Intervention: IABP insertion before PCI
Number of subjects: 275

Group type: COMPARATOR
Intervention: IABP insertion after PCI
Number of subjects: 275
Study: 36273066

Group type: EXPERIMENTAL
Intervention: CoQ10 + pregabalin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo + pregabalin
Number of subjects: 112
Study: 33293212

Group type: EXPERIMENTAL
Intervention: Icenticaftor 450 mg bid for 14 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 33970500

Group type: EXPERIMENTAL
Intervention: 16-week (25-hour) mathematics Professional Development (PD) model
Number of subjects: 225
Study: 32038023

Group type: EXPERIMENTAL
Intervention: Hemolen® ointment applied twice daily for 30 days
Number of subjects: 48
Study: 34612092

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) viral load testing
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard viral load testing (SOC)
Number of subjects: 150
Study: 33624584

Group type: EXPERIMENTAL
Intervention: New favipiravir tablet formulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference favipiravir tablet formulation
Number of subjects: 30
Study: 32886923

Group type: EXPERIMENTAL
Intervention: Respectful family planning service provision
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Short acting method client
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Uneducated client
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Client with elementary education
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Client’s poverty
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Long waiting time
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Preference of male service providers
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Service providers’ work satisfaction
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Health workers’ prior training on respectful care
Number of subjects: 920
Study: 34871817

Group type: EXPERIMENTAL
Intervention: Machine learning-based algorithm (random forest)
Number of subjects: 2325

Group type: COMPARATOR
Intervention: Conventional TET
Number of subjects: 2325
Study: 32386022

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 187
Study: 34548165

Group type: EXPERIMENTAL
Intervention: 1,000 mg IV acetaminophen (group A)
Number of subjects: 159

Group type: COMPARATOR
Intervention: 1,000 mg PO acetaminophen (group B)
Number of subjects: 159

Group type: COMPARATOR
Intervention: IV and PO placebo (group C)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 159
Study: 33260144

Group type: EXPERIMENTAL
Intervention: Multimodal proprioceptive exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 19

Group type: COMPARATOR
Intervention: Classroom-based control
Number of subjects: 19
Study: 32693842

Group type: EXPERIMENTAL
Intervention: Combined physical and psychological BOOST group physiotherapy programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best practice advice (Control)
Number of subjects: 0
Study: 36288445

Group type: EXPERIMENTAL
Intervention: FICare intervention
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 13
Study: 32174342

Group type: EXPERIMENTAL
Intervention: Cyclic assembly under four conditions (line‐type, batch‐type)
Number of subjects: 15
Study: 616840380

Group type: EXPERIMENTAL
Intervention: Intraorbital electroacupuncture therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neural nutrition drug (given to both groups)
Number of subjects: 60
Study: 36921715

Group type: COMPARATOR
Intervention: BNT161b2/30μg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: monovalent-Omi.BA.1/30μg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: monovalent-Omi.BA.1/60μg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: bivalent-Omi.BA.1/30μg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: bivalent-Omi.BA.1/60μg
Number of subjects: 122
Study: 33560089

Group type: EXPERIMENTAL
Intervention: Pancrelipase
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 36221431

Group type: EXPERIMENTAL
Intervention: Stress management coaching
Number of subjects: 109

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 109
Study: 32918079

Group type: EXPERIMENTAL
Intervention: Aspirin use >60 days/year
Number of subjects: 12101

Group type: COMPARATOR
Intervention: Aspirin use ≤60 days/year
Number of subjects: 12101
Study: 33559061

Group type: EXPERIMENTAL
Intervention: Epidemiologic information inserted into spine imaging reports
Number of subjects: 170680
Study: 32522263

Group type: EXPERIMENTAL
Intervention: ICT-based centralized monitoring group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 34328060

Group type: EXPERIMENTAL
Intervention: Differential reinforcement of approximations
Number of subjects: 3

Group type: COMPARATOR
Intervention: Terminal reinforcement
Number of subjects: 3
Study: 32534120

Group type: EXPERIMENTAL
Intervention: GeGen Decoction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35493824

Group type: EXPERIMENTAL
Intervention: t-DCS (n = 13) for 5 daily sessions (20 min−2 mA) with bi-hemispheric stimulation over the primary motor cortex (M1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham stimulation (n = 15) with the same duration and cadence
Number of subjects: 28
Study: 36217190

Group type: EXPERIMENTAL
Intervention: Local cooling permitted during passive exposure to humid heat
Number of subjects: 10
Study: 33720895

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) for 12 weeks
Number of subjects: 56
Study: 32345452

Group type: EXPERIMENTAL
Intervention: Combined treatment with suboccipital muscle inhibition and interferential current (20 minutes, twice weekly for 4 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 25
Study: 34571194

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) only for patients (Arm 1)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) for patients and caregivers (Arm 2)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Standard of care (Arm 3)
Number of subjects: 510
Study: 34275476

Group type: EXPERIMENTAL
Intervention: Standard care plus fosinopril
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study: 35552513

Group type: EXPERIMENTAL
Intervention: IV paracetamol (1000 mg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: IM tramadol (100 mg)
Number of subjects: 110
Study: 34431879

Group type: EXPERIMENTAL
Intervention: Lubricant eyedrops from five different brands
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Standard laboratory equipment for measuring eyedrop mass
Number of subjects: 5
Study: 33633687

Group type: EXPERIMENTAL
Intervention: Increase in daily GH dose (IGF-1 target level of 1 to 2 SDS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Decrease in daily GH dose (IGF-1 target level of -2 to -1 SDS)
Number of subjects: 32
Study: 32571329

Group type: EXPERIMENTAL
Intervention: Modified short-term fasting (mSTF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketogenic diet (KD) as fasting supportive diet
Number of subjects: 30
Study: 35535532

Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation, treated once every other day for 4 weeks.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Eperisone hydrochloride tablets combined with TSLO brace, oral eperisone hydrochloride tablets 50 mg three times a day, wearing TSLO brace for not less than 8 hours a day for 4 weeks.
Number of subjects: 120
Study: 32372277

Group type: EXPERIMENTAL
Intervention: Landiolol at 1 μg/kg/min
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Landiolol at 2 μg/kg/min
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no landiolol)
Number of subjects: 150
Study: 33213202

Group type: EXPERIMENTAL
Intervention: cVEMP test in psoriasis patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DPOAE test in psoriasis patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 43
Study: 34216177

Group type: EXPERIMENTAL
Intervention: NEPA (single dose of oral netupitant/palonosetron)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aprepitant (3-day regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NEPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aprepitant
Number of subjects: 0
Study: 32692701

Group type: EXPERIMENTAL
Intervention: Anise (Pimpinella Anisum) 110 mg capsules three times a day (total 330 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (starch capsules)
Number of subjects: 67
Study: 36121830

Group type: EXPERIMENTAL
Intervention: Systematic medication review conducted by clinical pharmacists during emergency department stay.
Number of subjects: 789

Group type: COMPARATOR
Intervention: Standard care from emergency department physicians and nurses (Control group).
Number of subjects: 789
Study: 33092803

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (post‐tetanic count 1–2 twitches)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Moderate neuromuscular block (train‐of‐four 1–2 twitches)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Number of subjects: 98

Group type: COMPARATOR
Intervention: Moderate neuromuscular block
Number of subjects: 98
Study: 35114667

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (group A1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech vaccine (group B1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group for CoronaVac (group A2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group for Pfizer-BioNTech (group B2)
Number of subjects: 27
Study: 33212111

Group type: EXPERIMENTAL
Intervention: Supervised exercise training 3 times/week for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (Untrained)
Number of subjects: 18
Study: 32150078

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT)
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) alone
Number of subjects: 2280
Study: 35022545

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (nutrition education, physical education)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study: 34841935

Group type: EXPERIMENTAL
Intervention: Baby-Friendly Hospital Initiative
Number of subjects: 131
Study: 33618281

Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV) with ECCO2R when PaCO2 > 55 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultra-LPV with ECCO2R for all
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lung protective ventilation (LPV) with ECCO2R
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultra-LPV with ECCO2R
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical ventilation (MV)
Number of subjects: 0
Study: 33270038

Group type: EXPERIMENTAL
Intervention: Pro-vaccine posts (n=324)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Anti-vaccine posts (n=256)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Antivaccine misinformation characteristics
Number of subjects: 580

Group type: COMPARATOR
Intervention: Information/resource posts
Number of subjects: 580

Group type: COMPARATOR
Intervention: Personal narrative posts
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Most liked pro-vaccine post
Number of subjects: 580

Group type: COMPARATOR
Intervention: Most liked anti-vaccine post
Number of subjects: 580
Study: 34747516

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (4000 IU/d)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 35568638

Group type: EXPERIMENTAL
Intervention: Nasal tube stabilization (NTS) with wire-reinforced tube
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nasal tube stabilization (NTS) with RAE tube
Number of subjects: 24

Group type: COMPARATOR
Intervention: Wire-reinforced tube (before NTS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: RAE tube (before NTS)
Number of subjects: 24
Study: 33223228

Group type: EXPERIMENTAL
Intervention: 5% Lidocaine Patch (LP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo Patch
Number of subjects: 57
Study: 35307066

Group type: EXPERIMENTAL
Intervention: NCPAP combined with inhalation of pulmonary surfactant using vibrating mesh nebulizers
Number of subjects: 42

Group type: COMPARATOR
Intervention: NCPAP combined with inhalation of pulmonary surfactant using endotracheal tube (INSURE)
Number of subjects: 42
Study: 34344839

Group type: EXPERIMENTAL
Intervention: Octenidine solution
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both interventions (Octenidine and Saline)
Number of subjects: 55
Study: 34644432

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 7
Study: 35050943

Group type: EXPERIMENTAL
Intervention: Weierkang pills
Number of subjects: 108

Group type: COMPARATOR
Intervention: Folic acid combined with teprenone
Number of subjects: 108
Study: 33430937

Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE) with linear stapled anastomosis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open esophagectomy (OE) with circular stapled anastomosis
Number of subjects: 20
Study: 32458393

Group type: EXPERIMENTAL
Intervention: Conservative Sinusectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excision and primary off-midline closure
Number of subjects: 0
Study: 33278293

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 32460523

Group type: EXPERIMENTAL
Intervention: Vilazodone 15 mg/day
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Vilazodone 30 mg/day
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study: 35038433

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus trastuzumab
Number of subjects: 203

Group type: COMPARATOR
Intervention: Chemoradiotherapy alone
Number of subjects: 203
Study: 34802328

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (experimental group)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 189
Study: 32467546

Group type: EXPERIMENTAL
Intervention: Test preparation (Metformin/Glibenclamide 500mg/5mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference preparation (Metformin/Glibenclamide 500mg/5mg)
Number of subjects: 28
Study: 36132088

Group type: EXPERIMENTAL
Intervention: TPB-based training intervention (8 training sessions)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Traditional training (nutritional and physical activity recommendations)
Number of subjects: 87
Study: 33511201

Group type: EXPERIMENTAL
Intervention: Topical TXA (3 g of TXA in 100 mL saline after TKA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Topical Floseal® (10 mL of Floseal® intra-articularly during surgery)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (intra-articular saline injection only)
Number of subjects: 103
Study: 36266762

Group type: EXPERIMENTAL
Intervention: risankizumab 600 mg IV
Number of subjects: 1881

Group type: EXPERIMENTAL
Intervention: risankizumab 1200 mg IV
Number of subjects: 1881

Group type: EXPERIMENTAL
Intervention: risankizumab 180 mg SC
Number of subjects: 1881

Group type: EXPERIMENTAL
Intervention: risankizumab 360 mg SC
Number of subjects: 1881

Group type: COMPARATOR
Intervention: placebo IV
Number of subjects: 1881
Study: 32420786

Group type: EXPERIMENTAL
Intervention: Curcumin (500-mg capsules twice daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Curcumin vs Placebo
Number of subjects: 39
Study: 33819703

Group type: EXPERIMENTAL
Intervention: Machine Learning-based radiomic model using MRI sequences (T1-weighted, T2-weighted, T2-FLAIR, postcontrast T1-weighted, and ADC maps)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Machine Learning-based radiomic model using MRI sequences
Number of subjects: 109
Study: 34219221

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 115

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 115
Study: 34401946

Group type: EXPERIMENTAL
Intervention: Surgical motor (machine-driven group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Torque wrench (manual group)
Number of subjects: 40
Study: 32927324

Group type: EXPERIMENTAL
Intervention: ERAS program
Number of subjects: 171

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 171
Study: 32872411

Group type: EXPERIMENTAL
Intervention: SNAP‐Ed
Number of subjects: 328
Study: 36078595

Group type: EXPERIMENTAL
Intervention: Financial Incentives for Quitting Smoking (FIMs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smoking Cessation Campaigns (CAMs)
Number of subjects: 0
Study: 33512695

Group type: EXPERIMENTAL
Intervention: Ottawa Emergency Department Shift Observation Tool (O-EDShOT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: daily encounter cards
Number of subjects: 24
Study: 32702315

Group type: EXPERIMENTAL
Intervention: AR101 oral immunotherapy
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 35674042

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 3313
Study: 35750106

Group type: EXPERIMENTAL
Intervention: Deep-learning signature
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Hybrid radiomics nomogram
Number of subjects: 302
Study: 34134903

Group type: EXPERIMENTAL
Intervention: Vibrotactile Feedback (VF) using VocaLog2 device
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lee Silverman Voice Treatment (LSVT LOUD®) combined with VF
Number of subjects: 8
Study: 33880813

Group type: EXPERIMENTAL
Intervention: Purslane extract (300 mg/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 32869230

Group type: EXPERIMENTAL
Intervention: EMS (mechanical simulator practice)
Number of subjects: 12

Group type: COMPARATOR
Intervention: non-EMS (control)
Number of subjects: 12
Study: 34039580

Group type: EXPERIMENTAL
Intervention: Early elective ascending aortic surgery
Number of subjects: 618

Group type: COMPARATOR
Intervention: Medical surveillance
Number of subjects: 618
Study: 32562683

Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg, subcutaneous injections once a week)
Number of subjects: 9901

Group type: COMPARATOR
Intervention: Placebo (equal volume of matching placebo, subcutaneous injections once a week)
Number of subjects: 9901
Study: 36396438

Group type: EXPERIMENTAL
Intervention: Cryoballoon Pulmonary Vein Isolation (PVI)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Radiofrequency CTI ablation
Number of subjects: 113
Study: 33333295

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 2 weeks
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: All tralokinumab doses
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 32854474

Group type: EXPERIMENTAL
Intervention: Unicornuate uterus group (vaginal delivery)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Unicornuate uterus group (cesarean section)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (vaginal delivery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (cesarean section)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postpartum hemorrhage (vaginal delivery)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postpartum hemorrhage (cesarean section)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Time of first stage of labor
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Time of second stage of labor
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neonatal birth weight
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: One-minute Apgar score (premature)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Five-minute Apgar score (premature)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: One-minute Apgar score (full-term)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Five-minute Apgar score (full-term)
Number of subjects: 80
Study: 33947444

Group type: EXPERIMENTAL
Intervention: Patient-led surveillance (n = 300)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Clinician-led surveillance (n = 300)
Number of subjects: 600